Suzanne Oparil, MD, a professor of medicine, physiology, and biophysics and director of the vascular biology and hypertension program at the University of Alabama at Birmingham presented new research at the May 4, 2010 meeting of American Society of Hypertension that demonstrates a new drug called Qnexa suppresses appetite and lowers blood pressure.

Qnexa is a combination of the appetite suppressant phentermine with the anti-seizure drug topiramate.

Phentermine rapidly suppresses appetite. Topiramate is time released and suppresses appetite as well as producing the perception of satiety (fullness) over time. Qnexa also drops systolic blood pressure (the top number in a blood pressure measurement).

The results from the study of 4500 people show:
1) people who took the full dose of Qnexa once daily lost nearly 10% of their body weight; at six months,

2) people who took the medium dose of the pill lost 8% of their body weight at six months, and

3) people who took the lowest dose of the drug dropped about 5.1% of body weight at six months.

The drug is designed to treat obesity and the high blood pressure that usually accompanies obesity Candidates for Qnexa may include people with a BMI of 27 to 30

The FDA advisory panel will review the research in the summer of 2010. The review is usually the go ahead step for release to produce and market but it is not a guarantee. The two drugs are already FDA approved but a new review and approval is needed for the combination of the two drugs.

The phentermine is part of the “phen-fen” drug but the fen part of that drug was what caused high blood pressure in the lungs) and heart valve disease

Birmingham Alabama is one of the most obese cities in the United States. The approval of this drug could reduce federal and state costs for the treatment of obesity and the complications that come from obesity.

 

—-
Paul Hamaker
Birmingham Science News Examiner